Increased serum level of thymidine kinase 1 correlates with metastatic site in patients with malignant melanoma

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 643-648

  Wu, Bao Jin ^a   Li, Wen Peng ^b   Qian, Cheng ^c   Ding, Wei ^a   Zhou, Zhong Wen ^a   Jiang, Hua ^a,c  

^a FUDAN UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Melanoma; Prognosis; TK1

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; LOMUSTINE; RECOMBINANT ALPHA2B INTERFERON; THYMIDINE KINASE 1; VINCRISTINE; THYMIDINE KINASE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN METASTASIS; SUBCUTANEOUS METASTASIS; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; BLOOD; CANCER STAGING; FOLLOW UP; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; COMBINED MODALITY THERAPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877114535     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0591-0     Document Type: Article

References (20)

1. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528-35. doi: 10.1097/01.sla.0000090446.63327.40.
2. Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-34. doi: 10.1200/JCO.2006.08.1463.
3. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:452-74. doi: 10.1093/jnci/djp038.
4. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Melanoma Group of the European Organization for Research and Treatment of Cancer. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006;98:472-82. doi: 10.1093/jnci/djj103.
5. Florell SR, Smoller BR, Boucher KM, Grossman D, Harris RM, Bowen GM, Leachman SA. Sampling of melanocytic nevi for research purposes: a prospective, pilot study to determine effect on diagnosis. J Am Acad Dermatol. 2008;59:814-21.
6. Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res. 2006;66:10652-7. doi: 10.1158/0008-5472.CAN-06-0921.
7. Ke PY, Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol. 2004;24:514-26. doi: 10.1128/MCB.24.2.514-526.2004.
8. Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogues. Mini Rev Med Chem. 2004;4:341-50.
9. Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, Mao Y, Wu J, He Q. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods. 2003;277:157-69.
10. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol. 2006;13:266-72.
11. Madewell BR. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma. J Vet Intern Med. 2004;18:595-6.
12. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001;12:621-5.
13. Schwartz MK. Enzymes as prognostic markers and therapeutic indicators in patients with cancer. Clin Chim Acta. 1992;206:77-82.
14. O'Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1 - a prognostic and diagnostic indicator in ALL and AML patients. Leukemia. 2007;21:560-3. doi: 10.1038/sj.leu.2404536.
15. Zhang J, Jia Q, Zou S, Zhang P, Zhang X, Skog S, Luo P, Zhang W, He Q. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep. 2006;15:455-61.
16. Fujiwaki R, Hata K, Moriyama M, Iwanari O, Katabuchi H, Okamura H, Miyazaki K. Clinical value of thymidine kinase in patients with cervical carcinoma. Oncology. 2001;61:47-54.
17. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton Jr A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-48.
18. Liu Y, Ling Y, Qi Q, Tang Y, Xu J, Tong Z, Sheng G, Yang Q, Pan Y. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med. 2011;2:1177-81. doi: 10.3892/etm.2011.338.
19. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003;2:753-63.
20. Krauze MT, Tarhini A, Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. Semin Immunopathol. 2011;33:385-91.